strong core revenu growth
maintain buy rate maintain tp
estim tp base forward price-to-earnings
multipl ep give upsid
potenti also estim
top line revenu growth
estim base follow factor strong growth
revenu earn healthi margin expans
strong growth segment due increas revenu
market share strong growth invest cash
danah deliv strong result increas
revenu due strong
perform high-growth develop market
mid-teen adjust earn per share growth strong cash
geograph high-growth market revenu increas
high-singl digit china lead way develop
market saw mid-singl digit growth north
america western europ region gain
momentum sinc begin year
dhr gross margin increas bp
core oper margin increas bp strong
margin perform due high core growth good
execut particularli across life scienc diagnost
total revenu life scienc segment increas
due strong new product launch
like cytoflex lx flow cytometri biomek i-seri
compani name corporationtickerdhrstock ratingbuyunchangedindustri viewoverweightpositivepric juli week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth corp august
incom statement
 guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
diagnost segment revenu increas
due strong perform
immunoassay chemistri busi new product
total sale environment appli solut segment
increas total revenu
dental segment increas
juli announc intent spin-
dental busi independ publicli
trade compani name dentalco
dhr recent acquisit great start
revenu increas double-digit rate
ep increas gener
free cash flow ytd result
expect achiev mid-single-digit core revenu
growth adjust ep expect
rang ep rang
expect ep
rang non-gaap adjust ep
rang
current price-to-earnings multipl
price-to-earnings average price-to-earnings
decemb trade
expect forward price-to-earnings multipl
dhr ytd stock perform compar
 roa roi roe ttm basi
stood respect
recommend buy rate stock base
perform strong portfolio product
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jul ex-dividend date jun last split factor new per last split date jul inform danah corp august
incom statement
 guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg oper oper profit interest incom special charges- interest incom minor incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli corp august
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item danah corp august
oper cash flow continu oper increas due higher
earn higher cash provid trade account receiv inventori account payabl
period compar prior year
net cash use invest activ continu oper compar
cash use
financ activ continu oper provid cash compar
cash use y/i increas cash provid financ activ due higher
net proce commerci paper borrow issu commerci paper pay
portion acquisit price april
defer incom taxes- oper increas decreas increas decreas current assets- decreas increas decreas increas current decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu issuanc capit repurchas capit stock- payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end corp august
danah deliv strong result due strong growth revenu
healthi margin expans mid-teen adjust earn per share growth
total revenu increas compar
revenu increas due increas demand product
servic geograph high-growth develop market contribut
core sale growth
revenu high-growth market increas high single-digit rate
compar compar period led primarili
continu strength china high-growth market repres total
sale revenu develop market increas mid-singl
digit rate led primarili growth north america
cog increas compar
gross profit increas compar
gross margin increas compar
sg expens increas compar
sg declin bp compar
declin due benefit increas leverag dhr
gener administr cost base result higher sale volum
impact restructur impair relat charg
incur relat discontinu product line increas
partial off-set continu invest sale market growth
 expens increas compar
 flat total revenu
result due
strong growth
share growth strong
compar
increas
compar
oper
margin
total revenu
compar total
revenu
oper profit increas compar
oper margin total revenu
compar total revenu increas due higher
year-over-year cost associ variou new product develop sale
market growth invest higher raw materi cost net
impact higher core sale volum impact weaker dollar
interest expens compar
increas due higher averag interest rate outstand borrow
compar averag interest rate impact
weaker dollar partial off-set lower averag outstand
 commerci paper borrow compar
effect tax rate compar net
incom increas compar
gaap ep increas compar non-
gaap ep increas compar prior year period
ytd oper cash flow increas ytd
non-gaap free cash flow increas prior year
total revenu increas compar
cog increas compar
gross profit increas compar
gross margin compar
increas due higher y/i sale volum increas leverag certain
sg expens increas compar
sg declin compar
 expens compar
 flat total revenu
oper profit increas compar
oper margin compar
interest expens compar prior year period
effect tax rate compar
net incom increas compar
ep increas compar
ytd oper cash flow increas compar prior
year period ytd non-gaap free cash flow increas
danah report segment consist life scienc diagnost dental
environment appli solut
total revenu life scienc segment increas
compar core revenu grew
total revenu increas
compar price increas segment
contribut sale growth y/i basi
period
oper profit increas compar
oper profit margin increas
compar
compar
ep increas
compar
total revenu
increas
compar
higher core sale volum increment y/i cost save associ
restructur action continu product improv
initi taken impact weaker dollar net
increment y/i cost associ variou new product develop sale
market growth invest
core sale busi broad rang mass spectromet grew
y/i basi period
increas due strong sale growth high-growth market primarili
china north america
core sale microscopi product grew
month period across major end-market due partial demand
relat releas new product geograph demand microscopi
product increas primarili develop market led north america
demand busi flow cytometri particl count product line
strong across major geographi particular strength north
america china western europ period
recent product launch also contribut increas demand
core sale filtrat separ purif technolog increas
period increas led
continu growth biopharmaceut microelectron end-market
across major geographi
sale growth acquisit due acquisit april
provid addit sale earn growth opportun segment
expand segment product line divers includ new product
servic offer area genom consum potenti
futur acquisit complementari busi idt revenu grew y/i
basi growth across major geographi product line
core sale
busi broad rang
increas due strong
sale growth high-
primarili china
core sale
filtrat separ
increas led
continu growth
biopharmaceut
market across
total revenu diagnost segment increas
compar total revenu increas
compar
oper profit increas compar
oper profit increas
compar oper profit margin increas
compar
increas oper margin due higher core sale volum
increment y/i cost save associ restructur action
increas also due continu product improv initi taken
impact weaker dollar
period core sale grew
molecular diagnost busi driven test menu expans strong
growth develop market growth partial off-set
lower project sale high-growth market
total revenu
increas
compar
month period
core sale grew
molecular
driven test menu
expans strong
growth develop
core sale segment clinic lab busi increas y/i basi
period due increas demand
high-growth market led china increas demand
immunoassay chemistri product line drove major growth
period
core sale acut care diagnost busi increas y/i
month period due continu strong sale blood ga
immunoassay product line across major geographi particularli
strong growth high-growth market
core sale patholog diagnost busi grew y/i
month period led demand new product
advanc stain core histolog product line core sale increas
patholog diagnost busi across major geographi led north
america western europ china
total revenu dental segment increas
compar total revenu increas
compar core revenu growth
declin compar prior year period price
segment neg impact sale growth y/i basi
period reflect compon
oper profit increas compar
oper margin declin compar
decreas due increment y/i cost associ
sale market growth invest increas spend
product initi lower overal price net higher core sale
volum cost save associ product initi taken
impact weaker dollar
geograph y/i core revenu growth driven china
high-growth market period
month period growth off-set lower demand north
america western europ
core revenu growth specialti consum busi consist
implant system orthodont product led high-growth market
north america period
core sale dental equip tradit dental consum
slightli increas demand high-growth market larg
off-set weaker demand develop market
total revenu
increas
compar
geograph y/i
core revenu growth
driven china
high-growth
market
month
lower core sale dental equip tradit dental
consum product line north america off-set y/i growth
specialti consum categori primarili reflect effort
reduc amount inventori held sever distribut partner well
realign distributor manufactur dental industri
juli announc intent spin-off dental busi
independ publicli trade compani name
dentalco dentalco compris danah current dental segment
oper compani consist nobel biocar ormco kavo kerr
dentalco global team associ
headquart south california dentalco premier global partner
dental commun industry-lead brand provid world-class
innov servic solut custom
sinc dental gross margin increas bp sg
expens declin bp dental spend sale increas
bp continu invest new product develop
across portfolio consolid number oper compani
nobel biocar nearli implant busi invest
increas launch new product
increas sale forc invest put dental
busi better posit acceler growth trajectori drive
continu margin expans busi togeth gener
gross margin
believ dental busi effect stand-alone
compani greater focu around organ inorgan invest
opportun includ also believ spin-off drive
greater sharehold valu dentalco
juli
announc intent
spin-off dental
busi
believ dental
busi
effect stand-alone
compani greater
focu around organ
target complet dental separ second half
subject satisfact certain condit includ obtain final approv
danah board director satisfactori complet financ
receipt tax opinion receipt favor rule ir receipt
regulatori approv
total sale environment appli solut segment increas
compar total revenu increas
compar core revenu
growth increas price increas
segment contribut sale growth y/i basi
month period reflect compon core
oper profit increas compar
oper margin compar
increas due higher y/i cost associ variou new
product develop sale market growth invest higher raw
materi cost impact weaker dollar
core sale segment water qualiti busi grew high-singl digit
rate period y/i core sale
analyt instrument product line increas
month period driven higher demand across major geographi led
china north america western europ
core revenu growth busi chemic treatment solut product
line period driven higher demand
primari metal paper mine commerci institut end-market
total sale
increas
compar
partial off-set lower demand food chemic end-market
period well oil ga end-market
period geograph y/i core revenu growth chemic treatment
solut driven increas demand north america high-growth
market three six-month period
core sale busi ultraviolet water disinfect product line increas
period led strength
municip end-market geograph y/i core revenu growth
ultraviolet water disinfect product driven higher demand north
america period north america china period
partial off-set softer demand western europ period
core sale segment product identif busi grew mid-
singl digit rate period
continu strong y/i demand mark code equip relat
consum major geographi led western europ north
america high-growth market drove major core revenu
demand packag color solut product servic decreas
slightli period essenti flat
period geograph y/i core revenu growth packag
color solut product servic driven develop market larg
off-set weaker demand high-growth market period
period weaker demand develop market off-set
increas demand high-growth market
demand mark
code equip
relat consum
major geographi
led western
high-growth
market drove
major core
guidanc conclus
expect ep rang non-gaap
adjust ep rang
expect adjust ep ep
rang
danah deliv strong result due strong perform high-
growth develop market continu growth segment
adjust earn per share growth strong cash flow danah revenu
increas adjust ep increas
gener free cash flow
gross margin increas bp net incom
increas margin perform improv
due higher core growth good execut across life scienc
per share growth
perform
compar
roe ttm basi
stood
total revenu life scienc segment increas
due strong new product launch like cytoflex lx flow cytometri
biomek i-seri autom diagnost segment revenu
increas due strong perform
immunoassay chemistri busi new product launch total sale
environment appli solut segment increas
total revenu dental segment increas
juli announc intent spin-off dental busi
independ publicli trade compani name dentalco
expect spin-off creat sharehold valu
dentalco spin-off complet second half
dhr ytd stock perform compar
roa roi roe ttm basi stood respect
non- reconcili
non- reconcili
non- reconcili
incom statement
 guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin increas ttm compar due decreas cog
oper margin increas ttm compar
y/i revenu growth increas ttm compar
ep growth ttm compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth corp august
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale danah corp august
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrq ratio growth yoy oper growth yoy free growth mrqreturn mrqcapex salescap ex salesfre mrqreturn asset danah corp august
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item danah corp august
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas investment- sale issuanc repurchas stock- net issuanc prefer stock- net issuanc net chang capit free corp august
current price-to-earnings multipl price-to-earnings went average price-to-earnings
decemb trade expect forward price-to-earnings
multipl reach
incom statement
 guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdershar report outvaluepric row associ vanguard group inc massachusett servic fmr wellington manag compani morgan america parnassu invest top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard parnassu equiti price row capit appreci spdr etf vanguard institut fund-institut mf seri trust i-mf valu price row chip growth fund ishar fidel competit
developmentsdanah announc spin dental busi independ publicli trade compani corpor announc intent spin dental segment independ publicly-trad compani dentalco transact intend tax-fre sharehold expect complet second half believ dental busi effect stand-alone compani greater focu around organ inorgan invest opportun danah announc quarterli dividend corpor announc board director approv regular quarterli dividend share payabl onjuli holder record onjun acquir integr dna technolog corpor integr dna announc enter definit agreement acquir privately-held provid high-valu consum genom applic molecular biolog qpcr next gener sequenc synthet biolog gene edit molecular diagnost june corp august
incom statement
 guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
perform
compar
gross margin
higher compar
roa roi roe ttm
basi stood
respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit corp august
consensu view analyst trend stock
rate expect
lower
growth rate
dhr forward price-to-earnings
higher
dhr avgfive-year growth forecast usdgrowth high day day day estim comparisondhrindustri avg avgprice/earn yield corp august
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr danah corp august
incom statement
 guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price movement show volatil period current trade
stock given total return last month
stock price show upward trend last one year given total return last one year
stock reach high low
stock price shown upward trend past year given total return last
stock price saw huge surg august went juli
crispidea price target maintain base forward price-to-earnings multipl
ep deliv strong result due growth segment along
high-growth develop market estim strong perform given buy rate
stock
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
